title: Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
abstract: BACKGROUND
  Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long-acting risperidone, the first long-acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery.
  
  
  OBJECTIVE
  To assess the efficacy and safety of long-acting injectable risperidone in elderly patients with psychotic disorders.
  
  
  METHODS
  This is a subanalysis of 57 patients aged > or =65 years enrolled in an open-label study of long-acting risperidone that included 725 symptomatically stable patients with schizophrenia or schizoaffective disorder. Patients were assigned to receive 25, 50, or 75 mg of long-acting risperidone every 2 weeks for up to 50 weeks.
  
  
  RESULTS
  Fifty-seven elderly patients (mean +/- SE age, 70.9 +/- 0.7 years) were enrolled. Mean Positive and Negative Syndrome Scale (PANSS) total scores improved significantly throughout the study and at endpoint (p < 0.001). The PANSS factor scores (positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression) also significantly improved (p < 0.01). Clinical improvement (> or =20% reduction in PANSS total scores) was achieved by 49% of these stable patients, and 55% improved on the Clinical Global Impressions scale. Severity of movement disorders (Extrapyramidal Symptom Rating Scale scores) was reduced significantly. Adverse events reported in >10% of patients were insomnia (14%), constipation (12%), and bronchitis (12%).
  
  
  CONCLUSIONS
  Long-acting risperidone was associated with significant symptom improvements in stable elderly patients with schizophrenia or schizoaffective disorder. Treatment was well tolerated.
authors.affiliation: Janssen Medical Affairs, LLC, Titusville, New Jersey 08560, USA. rlasser@janus.nj.com
authors.forename: Robert A
authors.initials: RA
authors.lastname: Lasser
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Bossie
authors.forename: Young
authors.initials: Y
authors.lastname: Zhu
authors.forename: Georges
authors.initials: G
authors.lastname: Gharabawi
authors.forename: Mariëlle
authors.initials: M
authors.lastname: Eerdekens
authors.forename: Michael
authors.initials: M
authors.lastname: Davidson
mesh_terms: D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy*; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone